BDMS maintains its 2026 revenue growth target of 2-4% and EBITDA margin target of 24%. Hospital revenue rose 3% YoY in Oct and accelerated to 5% YoY in the first 14 days of Nov, supported by higher complex-care cases despite fading seasonal illnesses. Strategic investment in CAR-T Cell therapy offers long-term potential, although the near-term revenue should remain small. We expect YoY earnings growth to continue in 4Q26, supported by rising Oct-Nov revenue, although earnings should decline QoQ due to seasonality. We maintain our OUTPERFORM rating with a mid-2027 DCF TP of Bt24.8, slightly down from Bt25 after fine-tuning our earnings forecasts.
BDMS – 4Q26 improvement continues

4Q26 revenue growth to continue, supported by complex-care cases. BDMS maintains its 2026 revenue growth target of 2-4% (vs. +2% YoY in 9M26) and EBITDA margin target of 24% (vs. 24.1% in 9M26). Hospital revenue rose 3% YoY in Oct, driven by Thai (+4%) and international patients (+3%), and accelerated to 5% YoY in the first 14 days of Nov, supported by higher complex-care cases despite fading seasonal illnesses. This reflects efforts to strengthen physician availability, medical equipment, and treatment capabilities, particularly at provincial hospitals. Despite a 23% YoY decline in revenue from Middle Eastern patients (3-4% of total revenue) in Oct, growth from the US (+35%), Europe (+18%), Myanmar (+7%), and CLMV (+5%) supported overall international patient revenue growth. BDMS plans to further diversify its international patient base to mitigate geopolitical and travel-related risks.
Strategic investment in CAR-T Cell therapy. BDMS invested an additional Bt170mn in Genepeutic Bio (GNPT), raising its stake from 19.9% to 55%, to expand into CAR-T Cell cancer therapy, which genetically modifies patients’ immune cells to recognize and destroy cancer cells. GNPT is the first company in Thailand to receive Thai FDA approval for CAR-T 19, initially targeting blood cancers, with early patients largely comprising children. BDMS plans to expand treatment to adult blood cancer patients in 2027 and gradually scale up production capacity. Local production should significantly reduce treatment costs versus overseas treatment, which management estimates at at least Bt10mn per case and potentially up to Bt30mn. While the near-term revenue contribution should remain modest, the investment could improve access to advanced cancer treatment in Thailand and support regional patient inflows over the longer term, particularly given the absence of a clear CAR-T Cell leader in ASEAN.
Earnings fine-tuned downward. We cut our 2026-27 BDMS earnings forecasts by 4% to reflect 9M26 core profit coming in below our previous estimate. Nevertheless, we expect YoY earnings growth to continue in 4Q26, supported by rising Oct-Nov revenue, although earnings should decline QoQ due to seasonality. We maintain our OUTPERFORM rating with a mid-2027 DCF TP of Bt24.8, slightly down from Bt25, based on a WACC of 7.3% and long-term growth of 2.5%.
Risks. Global economic slowdown and geopolitical risk may cause clients to delay elective medical care and make it inconvenient for international patients to come to Thailand for treatment. We see ESG risk primarily in patient safety (social factor), although BDMS has implemented a variety of quality assurance systems to ensure continuous and high-quality patient care.

